{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=13&q=gene+therapy", "query": { "q": "gene therapy", "page": 13 }, "page_size": 10 }, "pagination": { "page": 13, "page_size": 10, "total_count": 5850, "total_pages": 585, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=14&q=gene+therapy&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=12&q=gene+therapy&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-13T04:36:58.930Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06071624", "title": "Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML.", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Myelomonocytic Leukemia" ], "interventions": [ { "name": "CD4CAR", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Huda Salman", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2024-02-21", "completion_date": "2043-12", "has_results": false, "last_update_posted_date": "2026-09-24", "last_synced_at": "2026-10-13T04:36:58.930Z", "location_count": 4, "location_summary": "Miami, Florida • Indianapolis, Indiana • The Bronx, New York + 1 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "The Bronx", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06071624" }, { "nct_id": "NCT07121920", "title": "Ex-vivo Confocal Imaging and Proteomic Profiling to Determine Treatment Response in Children With IBD", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "IBD (Inflammatory Bowel Disease)", "IBD", "IBD - Inflammatory Bowel Disease" ], "interventions": [ { "name": "Confocal Laser Endomicroscopy", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Cook Children's Health Care System", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "2 Years to 21 Years" }, "enrollment_count": 40, "start_date": "2025-09-01", "completion_date": "2028-07-01", "has_results": false, "last_update_posted_date": "2025-08-14", "last_synced_at": "2026-10-13T04:36:58.930Z", "location_count": 2, "location_summary": "Arlington, Texas • Fort Worth, Texas", "locations": [ { "city": "Arlington", "state": "Texas" }, { "city": "Fort Worth", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07121920" }, { "nct_id": "NCT02494882", "title": "Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Dasatinib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 12, "start_date": "2015-06-29", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2026-07-06", "last_synced_at": "2026-10-13T04:36:58.930Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02494882" }, { "nct_id": "NCT04093349", "title": "A Gene Transfer Study for Late-Onset Pompe Disease (RESOLUTE)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pompe Disease", "Pompe Disease (Late-onset)", "Glycogen Storage Disease Type 2", "Glycogen Storage Disease Type II", "LOPD", "Lysosomal Storage Diseases", "Acid Maltase Deficiency" ], "interventions": [ { "name": "SPK-3006", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "Spark Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2020-10-01", "completion_date": "2032-04", "has_results": false, "last_update_posted_date": "2024-11-27", "last_synced_at": "2026-10-13T04:36:58.930Z", "location_count": 10, "location_summary": "Phoenix, Arizona • Orange, California • Atlanta, Georgia + 7 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Orange", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04093349" }, { "nct_id": "NCT01234935", "title": "Dasatinib and Gemcitabine Hydrochloride or Gemcitabine Hydrochloride Alone in Treating Patients With Pancreatic Cancer Previously Treated With Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acinar Cell Adenocarcinoma of the Pancreas", "Duct Cell Adenocarcinoma of the Pancreas", "Recurrent Pancreatic Cancer", "Stage IA Pancreatic Cancer", "Stage IB Pancreatic Cancer", "Stage IIA Pancreatic Cancer", "Stage IIB Pancreatic Cancer", "Stage III Pancreatic Cancer" ], "interventions": [ { "name": "dasatinib", "type": "DRUG" }, { "name": "gemcitabine hydrochloride", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "mutation analysis", "type": "GENETIC" }, { "name": "nucleic acid sequencing", "type": "GENETIC" }, { "name": "immunohistochemistry staining method", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER", "GENETIC" ], "sponsor": "Translational Oncology Research International", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2011-01-13", "completion_date": "2017-11-27", "has_results": false, "last_update_posted_date": "2018-01-09", "last_synced_at": "2026-10-13T04:36:58.930Z", "location_count": 17, "location_summary": "Alhambra, California • Fullerton, California • Long Beach, California + 12 more", "locations": [ { "city": "Alhambra", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01234935" }, { "nct_id": "NCT01164917", "title": "Safety Study of AMG 811 in Subjects With Discoid Lupus Erythematosus", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cutaneous Lupus", "Discoid Lupus", "Lupus", "Systemic Lupus Erythematosus" ], "interventions": [ { "name": "AMG811", "type": "DRUG" }, { "name": "AMG811 Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 16, "start_date": "2010-08", "completion_date": "2013-03", "has_results": false, "last_update_posted_date": "2014-09-16", "last_synced_at": "2026-10-13T04:36:58.930Z", "location_count": 8, "location_summary": "Santa Monica, California • Stanford, California • Atlanta, Georgia + 5 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01164917" }, { "nct_id": "NCT04214418", "title": "Study of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Gastrointestinal Cancer" ], "interventions": [ { "name": "Cobimetinib", "type": "DRUG" }, { "name": "Hydroxychloroquine", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2020-02-12", "completion_date": "2022-07-01", "has_results": true, "last_update_posted_date": "2024-12-18", "last_synced_at": "2026-10-13T04:36:58.930Z", "location_count": 2, "location_summary": "New York, New York • Providence, Rhode Island", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT04214418" }, { "nct_id": "NCT02442115", "title": "Impact of Improving Gastrointestinal Symptoms on Autism Symptoms and Oxidative Stress", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Autistic Disorder", "Constipation", "Gastrointestinal Diseases" ], "interventions": [ { "name": "Treatment of Functional Constipation by", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Children's Hospital Los Angeles", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "5 Years to 17 Years" }, "enrollment_count": 100, "start_date": "2015-04-29", "completion_date": "2019-02-06", "has_results": false, "last_update_posted_date": "2024-12-20", "last_synced_at": "2026-10-13T04:36:58.930Z", "location_count": 2, "location_summary": "Los Angeles, California • Santa Ana, California", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Santa Ana", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02442115" }, { "nct_id": "NCT00001476", "title": "Gene Therapy for Chronic Granulomatous Diseases - Long-term Follow-up", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Granulomatous Disease", "Communicable Disease" ], "interventions": [ { "name": "Gene Therapy Method for CGD", "type": "DRUG" }, { "name": "Isolex 300i Magnetic Cell Selector", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": null, "sex": "ALL", "summary": "5 Years and older" }, "enrollment_count": 14, "start_date": "1995-06-01", "completion_date": "2010-12-13", "has_results": false, "last_update_posted_date": "2017-07-02", "last_synced_at": "2026-10-13T04:36:58.930Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001476" }, { "nct_id": "NCT07148089", "title": "A Study of SGT-501 Gene Therapy in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Catecholaminergic Polymorphic Ventricular Tachycardia" ], "interventions": [ { "name": "SGT-501", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Solid Biosciences Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "7 Years", "maximum_age": null, "sex": "ALL", "summary": "7 Years and older" }, "enrollment_count": 18, "start_date": "2026-02-23", "completion_date": "2031-05", "has_results": false, "last_update_posted_date": "2026-09-24", "last_synced_at": "2026-10-13T04:36:58.930Z", "location_count": 4, "location_summary": "Boston, Massachusetts • Rochester, Minnesota • Cleveland, Ohio + 1 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07148089" } ] }